 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > A multicentre validation study of the diagnostic value of plasma neurofilament light |
(NIHR Biomedical Research Centre for Mental Health (Londres, Regne Unit)) (Department of Basic and Clinical Neuroscience. Maurice Wohl Clinical Neuroscience Institute. King's College London) (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center) (Department of Psychiatry and Neurochemistry. Institute of Neuroscience & Physiology. The Sahlgrenska Academy at the University of Gothenburg) (Institut d'Investigació Biomèdica Sant Pau) (Laboratory of Clinical Neurochemistry. Neurology Clinic. University of Perugia) (University of Milan) (Parkinson's Disease Rehabilitation Centre. FERB ONLUS) (Neurology Unit. Department of Clinical and Experimental Sciences. University of Brescia) (Sahlgrenska University Hospital (Suècia)) (Department of Health Sciences. University of Leicester) (University of California San Francisco. Memory and Aging Center) (Stress. Psychiatry and Immunology Lab & Perinatal Psychiatry. Maurice Wohl Clinical Neuroscience Institute. King's College London) (King's College London (Regne Unit)) (Department of Neurodegenerative Disease. Queen Square Institute of Neurology. University College London) (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) (King's College Hospital NHS Foundation Trust) (Stavanger University Hospital) (Lund University. Skåne University Hospital) (University College London. UK Dementia Research Institute) (Sahlgrenska University Hospital (Suècia)) (Stavanger University Hospital) (Skåne University Hospital (Suècia))
| Data: | 2021 |
| Resum: | Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We demonstrate that plasma NfL is clinically useful in identifying atypical parkinsonian disorders in patients with parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related clinical cut-offs for disorders with a younger age of onset. Finally, plasma NfL performs best when applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs. |
| Ajuts: | European Commission 259867 European Commission. Horizon 2020 H2020-PHC-2014-two-stage European Commission. Horizon 2020 633413 European Commission. Horizon 2020 772376 European Research Council 681712 |
| Nota: | Altres ajuts: National Institute for Health Research (NIHR) Biomedical Research Centre, South London; Maudsley NHS Foundation Trust; King's College London; MND Association; Wellcome Trust; United Kingdom, Medical Research Council (MR/L501529/1, MR/R024804/1); Economic and Social Research Council (ES/L008238/1); Swedish Research Council; Knut and Alice Wallenberg Foundation; Marianne and Marcus Wallenberg Foundation; Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease), Lund University; Swedish Brain Foundation; Parkinson Research Foundation; Skåne University Hospital Foundation; Swedish federal government (ALF agreement); National Institute on Aging (NIA); National Institutes of Health (NIH); Wallenburg Centre for Molecular and Translational; Swedish Alzheimer Foundation (Alzheimerfonden); Swedish Dementia Foundation (Demensfonden), Hjärnfonden (#FO2020-0241); Gamla Tjänarinnor; Motor Neurone Disease Association (MNDA); NIHR Maudsley Biomedical Research Centre; Neuromuscular diseases (GEEN), Spanish Society of Neurology (SEN); Wellcome Trust Strategic Award (098330/Z/12/Z conferred upon The London Down Syndrome (LonDownS) Consortium); UK Medical Research Council (MRC S011277/1, MR/S005145/1 via Centres of Excellence in Neurodegeneration research, and MR/R024901/1); National Institute for Health Research networks (mental health, dementias, and neurology); NHS trusts; CBD solutions; Stockholm City Council; Swedish Foundation for Strategic Research; Van Geest Foundation; Swedish Research Council (#2018-02532); Swedish State Support for Clinical Research (#ALFGBG-720931); UK Dementia Research Institute at UCL; Torsten Söderberg Foundation, Stockholm. |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Matèria: | Age Factors ; Aged ; Biomarkers ; Cognitive Dysfunction ; Cohort Studies ; Depression ; Down Syndrome ; False Positive Reactions ; Female ; Humans ; Male ; Middle Aged ; Neurodegenerative Diseases ; Neurofilament Proteins ; Predictive Value of Tests ; Reference Values ; Sex Factors |
| Publicat a: | Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 3400, ISSN 2041-1723 |
